DUBLIN, May 22, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) today launched IBSDonTract.com, an online resource for those living with irritable bowel syndrome with diarrhea (IBS-D). IBS-D, which affects approximately 15 million adults in the U.S., is a functional bowel disorder commonly characterized by chronic abdominal pain and frequent diarrhea. The new website is a part of Allergan's continued efforts to help educate the public and patients about IBS-D, and includes key information about symptoms, condition management and tips on speaking with a healthcare provider about IBS-D.
"IBS-D can have a significant impact on patients' daily lives – but in many cases, due to embarrassment or uncertainty about symptoms, patients wait years before seeing a doctor," said Gavin Corcoran, MD, FACP, Chief Medical Officer, Allergan. "IBSDonTract.com is an important resource for patients seeking to better understand the condition and their options. It also helps to explain why talking to their healthcare provider sooner rather than later is critically important, in order to shorten the time between symptom onset and effective disease management."
According to findings from the American Gastroenterological Association's (AGA) "IBS in America Survey," the most comprehensive IBS survey ever conducted, polling more than 3,200 sufferers and 300 physicians, 66 percent of patients suffer with symptoms for more than a year before talking with a doctor and 11 percent of patients wait a decade or more before seeking medical help. IBSDonTract.com features information that can help patients have a more productive conversation with their healthcare provider, including resources such as a symptom tracker, self-assessment tool and doctor discussion guide.
For more information about IBS-D and tools for management and treatment, please visit https://www.IBSDonTract.com/.
Irritable bowel syndrome with diarrhea (IBS-D) is a functional bowel disorder characterized by chronic abdominal pain and frequent diarrhea, which affects approximately 15 million patients in the U.S. Although the exact cause of IBS-D is not known, symptoms are thought to result from a disturbance in the way the gastrointestinal tract and nervous system interact.
IBS-D can be debilitating and there are limited therapeutic options for managing the chronic symptoms. IBS-D is associated with economic burden in direct medical costs and indirect social costs such as absenteeism and lost productivity, along with decreased quality of life.
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.
For more information, visit Allergan's website at www.allergan.com.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the risks associated with acquisition transactions; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (such periodic public filings having been filed under the "Actavis plc" name) and from time to time in Allergan's other investor communications . Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
(862) 261 7558
(973) 517 3132
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/allergan-launches-ibs-d-on-tract-new-online-resource-to-support-patients-with-irritable-bowel-syndrome-with-diarrhea-ibs-d-300272732.html
SOURCE Allergan plc